| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Across the last three months, Camp4 Therapeutics Corporation's insiders have reduced their positions by a net 583,613 shares worth roughly $2.5M.
Counted by filing, the last 12 months brought 5 open-market purchases by 4 insiders worth about $99K and 4 sales by 2 insiders worth about $2.5M. The 12 months before that brought 5 open-market purchases by 5 insiders worth about $2.1M and no sales.
None of the 4 sales in the last 12 months was marked as made under a Rule 10b5-1 trading plan.
The largest open-market purchase in the last two years was 1,307,189 shares by Amir Nashat (Director, 10% Owner) at an average $1.53 on September 11, 2025, about $2.0M. Twelve months later CAMP was up 53%.
The most recent purchase was by Kelly Gold (Chief Financial Officer) on August 31, 2026.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 2.03M | $7.79M | - | |
| CEO | 285.0K | $1.09M | - | |
| Dir | 186.4K | $713.9K | - | |
| Other | 12.6K | $48.3K | - | |
| CFO | 10.0K | $38.3K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 31, 2026 | Kelly Gold | Chief Financial Officer | Buy | 10,000 | $3.96 | $39,600.00 | New | - | - | |
| Aug 27, 2026 | Andrew J. Schwab61 | Director | Sell | 400,000 | $4.04 | $1,616,000.00 | -16.4% | - | - | |
| Aug 24, 2026 | Andrew J. Schwab61 | Director | Sell | 10 | $4.50 | $45.00 | - | - | - | |
| Aug 21, 2026 | Andrew J. Schwab61 | Director | Sell | 191,865 | $4.59 | $879,718.72 | -7.3% | - | - | |
| Aug 19, 2026 | Daniel Tardiff | Chief Scientific Officer | Sell | 1,738 | $4.76 | $8,272.88 | -100% | - | - | |
| Aug 3, 2026 | Richard A Young | Director | Buy | 16,378 | $1.65 | $27,023.70 | +9.6% | -7.4% | - | |
| Aug 3, 2026 | Kelly Gold | Chief Financial Officer | Buy | 6,551 | $1.65 | $10,809.15 | +9.7% | -7.4% | - | |
| Aug 3, 2026 | Josh Mandel-Brehm | Chief Executive Officer | Buy | 6,551 | $1.65 | $10,809.15 | +2.4% | -7.4% | - | |
| Aug 3, 2026 | Yuri Maricich | Chief Medical Officer | Buy | 6,551 | $1.65 | $10,809.15 | +108.1% | -7.4% | - | |
| Sep 11, 2025 | Polaris Management Co. VII, L.l.c. | 10% Owner | Buy | 1,307,189 | $1.53 | $1,999,999.17 | -117.8% | +105.8% | +52.9% |